We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Investors Should Hold DaVita (DVA) Stock Now
Read MoreHide Full Article
DaVita Inc. (DVA - Free Report) is gaining prominence in the MedTech space, courtesy of its incessant efforts to upgrade services, global expansion initiatives and acquisitions. The company has a market capitalization of approximately $9.80 billion.
However, DaVita incurred additional expenses in fourth-quarter 2018. These expenses include $30 million of advocacy costs in countering union policy efforts including ballot initiatives. Additionally, it incurred an additional charge of $252 million on the DMG business and a $42-million goodwill impairment charge.
In a year’s time, this Zacks Rank #3 (Hold) stock has lost 19.1%, significantly wider than the industry’s 11.5% decline.
Here we take a quick look at the factors that ensure near-term recovery of DaVita’s dull price performance.
Factors to Boost DaVita
DaVita has been steadily expanding in international markets. In the last few years, the company has strengthened its position in the emerging and developing markets of Brazil, China, Colombia, Germany, India, Malaysia, the Netherlands, Poland, Portugal and Saudi Arabia through strategic alliances as well as acquisitions of dialysis centers.
These strategic efforts are expected to help DaVita deliver more efficient patient care. Currently, DaVita is seeking to expand in major European and Asian countries via acquisitions and partnerships. In the fourth quarter, international dialysis patient service and other revenues totaled $124 million, up 30.5% year over year.
In the United States, DaVita has witnessed strong demand of dialysis services in recent times. In the fourth quarter of 2018, the company provided dialysis services at 2,905 outpatient dialysis centers, of which 2,664 centers were located in the United States and 241 in nine countries outside the country. Notably, fourth-quarter U.S. dialysis and related lab services’ revenues grossed $2.63 billion, up 10% from the prior-year quarter.
Which Way Are Estimates Headed?
For 2019, the Zacks Consensus Estimate for revenues is pegged at $11.60 billion, up 1.7% year over year. For adjusted earnings, the same is pinned at $4.42, up 23.8% year over year.
A few better-ranked stocks in the MedTech space are Surmodics, Inc (SRDX - Free Report) , Abbott Laboratories (ABT - Free Report) and Cardiovascular Systems, Inc. .
Abbott’s long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2 (Buy).
Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters, the average being 77.1%. The stock sports a Zacks Rank of 1.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Here's Why Investors Should Hold DaVita (DVA) Stock Now
DaVita Inc. (DVA - Free Report) is gaining prominence in the MedTech space, courtesy of its incessant efforts to upgrade services, global expansion initiatives and acquisitions. The company has a market capitalization of approximately $9.80 billion.
However, DaVita incurred additional expenses in fourth-quarter 2018. These expenses include $30 million of advocacy costs in countering union policy efforts including ballot initiatives. Additionally, it incurred an additional charge of $252 million on the DMG business and a $42-million goodwill impairment charge.
In a year’s time, this Zacks Rank #3 (Hold) stock has lost 19.1%, significantly wider than the industry’s 11.5% decline.
Here we take a quick look at the factors that ensure near-term recovery of DaVita’s dull price performance.
Factors to Boost DaVita
DaVita has been steadily expanding in international markets. In the last few years, the company has strengthened its position in the emerging and developing markets of Brazil, China, Colombia, Germany, India, Malaysia, the Netherlands, Poland, Portugal and Saudi Arabia through strategic alliances as well as acquisitions of dialysis centers.
These strategic efforts are expected to help DaVita deliver more efficient patient care. Currently, DaVita is seeking to expand in major European and Asian countries via acquisitions and partnerships. In the fourth quarter, international dialysis patient service and other revenues totaled $124 million, up 30.5% year over year.
In the United States, DaVita has witnessed strong demand of dialysis services in recent times. In the fourth quarter of 2018, the company provided dialysis services at 2,905 outpatient dialysis centers, of which 2,664 centers were located in the United States and 241 in nine countries outside the country. Notably, fourth-quarter U.S. dialysis and related lab services’ revenues grossed $2.63 billion, up 10% from the prior-year quarter.
Which Way Are Estimates Headed?
For 2019, the Zacks Consensus Estimate for revenues is pegged at $11.60 billion, up 1.7% year over year. For adjusted earnings, the same is pinned at $4.42, up 23.8% year over year.
DaVita Inc. Price and Consensus
DaVita Inc. Price and Consensus | DaVita Inc. Quote
Key Picks
A few better-ranked stocks in the MedTech space are Surmodics, Inc (SRDX - Free Report) , Abbott Laboratories (ABT - Free Report) and Cardiovascular Systems, Inc. .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Abbott’s long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2 (Buy).
Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters, the average being 77.1%. The stock sports a Zacks Rank of 1.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>